噻托溴铵联合舒利迭治疗中重度COPD稳定期患者疗效分析

Analysis of the Efficacy of Tiotropium Bromide Combined with Seretide in the Treatment of Patients with Moderate to Severe COPD in Stable Stage

目的探究噻托溴铵联合舒利迭治疗中重度COPD稳定期患者疗效情况。方法方便选择2018年1月—2019年10月该院接受治疗的83例中重度慢性阻塞性肺疾病患者设置为该次实验的对象。基于患者自主自愿原则,分组成立参照及实验两组。参照组采用单一舒利迭治疗;实验组则就参照组基础中联合给予噻托溴铵治疗。统计比对两组患者治疗前后的呼吸困难情况、肺功能指标及治疗效果。结果治疗前,两组呼吸困难及肺功能指标对比差异无统计学意义(P>0.05)。经治疗,实验组呼吸困难评分(1.55±0.21)分相较于参照组(1.94±0.22)呈显著优越性,差异有统计学意义(t=12.188,P<0.05);实验组两项肺功能指标优于参照组(P<0.05);实验组治疗总有效率(97.62%)相较于参照组(82.93%)呈明显优越性,差异有统计学意义(χ^2=2.602,P<0.05)。结论在治疗中重度慢性阻塞性肺疾病时应用噻托溴铵联合舒利迭治疗的疗效显著,能有效提高患者治疗质量,改善患者呼吸功能及心功能状况,促进患者恢复。

Objective To explore the efficacy of tiotropium bromide combined with seretide in the treatment of moderate to severe COPD patients in stable stage.Methods From January 2018 to October 2019,83 patients with moderate to severe chronic obstructive pulmonary disease who were treated in this hospital were convenient selected as the subjects of this experiment.Based on the principle of autonomy and voluntariness of patients,the two groups were divided into reference and experimental groups.The reference group was treated with seretide alone;the experimental group was treated with tiotropium bromide as the basis of the reference group.Statistically compare the dyspnea,lung function indicators and treatment effects of the two groups of patients before and after treatment.Results Before treatment,there was not statistically significant difference in dyspnea and lung function indexes between the two groups(P>0.05).After treatment,the dyspnea score of the experimental group(1.55±0.21)points was significantly superior to that of the reference group(1.94±0.22)points,the difference was statistically significant(t=12.188,P<0.05);the two lung function indexes of experimental group was better than the reference group;the total effective rate of treatment in the experimental group(97.62%)compared with the reference group(82.93%)showed obvious superiority,the difference was statistically significant(χ^2=2.602,P<0.05).Conclusion In the treatment of moderate to severe chronic obstructive pulmonary disease,the therapeutic effect of tiotropium bromide combined with seretide is significant,which can effectively improve the quality of treatment,improve the respiratory and cardiac function of the patient,and promote the recovery of the patient.